DAMAE Medical is a technology company.
DAMAE Medical has raised $6.0M across 1 funding round.
DAMAE Medical has raised $6.0M in total across 1 funding round.
DAMAE Medical has raised $6.0M in total across 1 funding round.
DAMAE Medical's investors include AQUITI Gestion, Kurma Partners.
DAMAE Medical is a French medtech company developing the deepLive™ imaging system, a handheld device based on line-field confocal optical coherence tomography (LC-OCT) technology for non-invasive, high-resolution 3D imaging of skin lesions at cellular level.[1][2][3] It serves dermatologists, oncologists, and clinicians by reducing unnecessary biopsies—often 70-80% of cases—improving early skin cancer detection (melanoma and non-melanoma), and enabling precise lesion margin assessment for surgery.[1][2][6] With over €22M raised (including €15M Series B in November 2025 led by Creadev), the company has deployed devices in 40+ global centers, backed by 250+ publications, and is integrating AI for diagnostics.[2][3][6]
DAMAE Medical spun out in 2014 from Institut d'Optique Graduate School (Palaiseau, France) by a team of photonics researchers, including Prof. Arnaud Dubois from Charles Fabry Laboratory (CNRS, Institut d’Optique, Université Paris-Saclay).[2][3][6] The idea stemmed from patented LC-OCT technology for biological imaging, adapted into a real-time skin diagnostic device after validating its potential for carcinomas and melanomas in 2015.[2][3] Early milestones included a 2016 clinical demonstrator at Saint-Etienne University Hospital, €2M seed funding in 2017 from Kurma Partners, Idinvest, and others, and a 2019 handheld 3D probe with 10 units produced for validation.[3] Pivotal traction came via EU-funded OCTAV project for market readiness and regulatory approval.[4]
DAMAE rides the AI-medtech wave in dermatology, addressing rising skin cancer incidence (global epidemic) amid biopsy overload and pathologist shortages.[1][6] Timing aligns with non-invasive diagnostics demand, post-COVID telehealth push, and EU/US regulatory nods for optical imaging.[4] Market tailwinds include aging populations, precision oncology, and digital pathology growth; LC-OCT fills the gap between dermoscopy (surface-only) and biopsy (invasive).[2][3] It influences ecosystems by enabling AI training on rich 3D datasets, collaborating with top clinics, and shifting guidelines toward "microscopic imagery-guided" procedures.[2][6]
DAMAE's €15M Series B fuels deepLive™ global rollout, AI enhancements, and surgical integrations, targeting routine clinical adoption and research data monetization.[6] Trends like multimodal AI diagnostics and personalized dermato-oncology will propel it, potentially capturing share in a $10B+ skin cancer market. Influence may evolve to platform leader, powering biopsy-free workflows and reducing healthcare costs—transforming DAMAE from spinout innovator to dermatology standard.[1][2][6]
DAMAE Medical has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Series A in February 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2022 | $6.0M Series A | AQUITI Gestion, Kurma Partners |